Nymox Pharmaceutical (NASDAQ:NYMX) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Nymox Pharmaceutical (NASDAQ:NYMXGet Rating) in a report issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Nymox Pharmaceutical Stock Down 4.3 %

Shares of Nymox Pharmaceutical stock opened at $0.32 on Monday. The company has a market capitalization of $28.52 million, a price-to-earnings ratio of -3.15 and a beta of 0.73. Nymox Pharmaceutical has a 12-month low of $0.19 and a 12-month high of $2.10. The firm’s 50-day moving average price is $0.36 and its two-hundred day moving average price is $0.47.

Institutional Investors Weigh In On Nymox Pharmaceutical

A number of large investors have recently bought and sold shares of NYMX. Citigroup Inc. acquired a new stake in shares of Nymox Pharmaceutical in the 1st quarter valued at approximately $137,000. Murchinson Ltd. acquired a new stake in shares of Nymox Pharmaceutical in the 1st quarter valued at approximately $96,000. WMS Partners LLC acquired a new stake in shares of Nymox Pharmaceutical in the 1st quarter valued at approximately $53,000. MAI Capital Management acquired a new stake in shares of Nymox Pharmaceutical in the 1st quarter valued at approximately $44,000. Finally, Warberg Asset Management LLC acquired a new stake in shares of Nymox Pharmaceutical in the 1st quarter valued at approximately $31,000. 0.97% of the stock is currently owned by institutional investors and hedge funds.

Nymox Pharmaceutical Company Profile

(Get Rating)

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma.

Read More

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.